Celyad Financial Statements From 2010 to 2025
| CLYYF Stock | USD 0.15 0.03 16.67% |
Check Celyad Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celyad Oncology's main balance sheet or income statement drivers, such as , as well as many indicators such as . Celyad financial statements analysis is a perfect complement when working with Celyad Oncology Valuation or Volatility modules.
Celyad |
Celyad Oncology SA Company Shares Outstanding Analysis
Celyad Oncology's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Celyad Oncology Shares Outstanding | 22.59 M |
Most of Celyad Oncology's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celyad Oncology SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Celyad Oncology SA has 22.59 M of shares currently outstending. This is 87.48% lower than that of the Healthcare sector and 78.86% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 96.05% higher than that of the company.
Celyad Oncology SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Celyad Oncology's current stock value. Our valuation model uses many indicators to compare Celyad Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Celyad Oncology competition to find correlations between indicators driving Celyad Oncology's intrinsic value. More Info.Celyad Oncology SA is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Celyad Oncology's earnings, one of the primary drivers of an investment's value.About Celyad Oncology Financial Statements
Celyad Oncology stakeholders use historical fundamental indicators, such as Celyad Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Celyad Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Celyad Oncology's assets and liabilities are reflected in the revenues and expenses on Celyad Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Celyad Oncology SA. Please read more on our technical analysis and fundamental analysis pages.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T cell-based therapies for the treatment of cancer. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Celyad Oncology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 87 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Celyad Pink Sheet
Celyad Oncology financial ratios help investors to determine whether Celyad Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celyad with respect to the benefits of owning Celyad Oncology security.